Minims Fenilefrina Hidrocloruro Bausch + Lomb Ireland Limited (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Minims Fenileprina Hidrocloruro Bausch + Lomb Ireland Limited, is an alpha‑adrenergic agonist presented as an ophthalmic solution for ocular use. It reduces ocular redness and provides relief of conjunctival hyperemia in adults and children as directed by a healthcare professional.

GNH USA supplies Minims Fenileprina Hidrocloruro Bausch + Lomb Ireland Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, eye‑care centres and clinics worldwide.

Phenylephrine Hydrochloride is used as an ocular decongestant to treat conditions involving conjunctival vasodilation.

Conjunctival hyperemia: reduces redness by constricting conjunctival blood vessels. Ocular redness due to minor irritation: provides rapid visual relief of redness. Post‑operative ocular swelling: helps diminish transient redness after eye procedures. Mild allergic conjunctivitis: lessens redness as part of supportive therapy.

Phenylephrine eye drops may cause local ocular reactions, ranging from mild irritation to rare serious events.

Common Side Effects: - Transient ocular stinging or burning - Mild eye irritation - Temporary blurred vision - Dryness of the ocular surface

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Significant increase in intraocular pressure - Corneal edema - Iridocyclitis

When using phenylephrine ophthalmic solution, consider the following safety measures.

Assess patient history: check for narrow‑angle glaucoma or severe hypertension. Avoid use in patients with uncontrolled hypertension: phenylephrine may raise systemic blood pressure. Do not exceed recommended frequency: overuse can increase risk of ocular irritation. Discontinue if severe irritation occurs: seek medical advice promptly. Store at room temperature: keep in the original container, protect from light and moisture.

Phenylephrine ophthalmic solution can interact with systemic and topical agents.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: additive vasoconstrictive effect. - Sympathomimetic agents: excessive systemic vasoconstriction.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: may enhance ocular pressure changes. - Other topical decongestants: risk of cumulative irritation. - Systemic antihypertensives: may reduce systemic effect of phenylephrine.